PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses. PJT operates businesses across strategic advisory, strategic capital markets, restructuring, shareholder advisory and capital raising. The firm has advised on over $1 trillion in M&A transactions including AbbVie's $63 billion acquisition of Allergan, T-Mobile's $59 billion merger with Sprint, and Mylan's $50 billion merger with Pfizer subsidiary, Upjohn.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PJT | PJT Partners Inc. | 2025-10-16 15:10:05 | 174.73 | 0.05 | 0.03 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PJT | 0001626115 | PJT Partners Inc. | US69343T1079 | 549300W3WBEQUBKYTN87 | 364797143 | NYSE | 6282 | Investment Advice | 1231 | DE | 280 PARK AVENUE | NEW YORK | NY | 10017 | UNITED STATES | US | 212-364-7800 | 280 PARK AVENUE, NEW YORK, NY, 10017 | 280 PARK AVENUE, NEW YORK, NY, 10017 | — | Investment banking | 2015 | — | 1,143 | http://pjtpartners.com/ | 2,500,000,000 | — | 24,800,541 | PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses. PJT operates businesses across strategic advisory, strategic capital markets, restructuring, shareholder advisory and capital raising. The firm has advised on over $1 trillion in M&A transactions including AbbVie's $63 billion acquisition of Allergan, T-Mobile's $59 billion merger with Sprint, and Mylan's $50 billion merger with Pfizer subsidiary, Upjohn. | 2025-10-10 19:59:03 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 2,500,000,000 | 900,000,000 | 56.25 | — | — | — |
| 2023 | 1,600,000,000 | -100,000,000 | -5.8824 | — | — | — |
| 2022 | 1,700,000,000 | 0 | 0 | — | — | — |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| David A. Travin | General Counsel | 2024 | 500,000 | 1,309,600 | 1,178,400 | — | — | 2,988,000 |
| Helen T. Meates | Chief Financial Officer | 2024 | 1,000,000 | 1,847,700 | 1,640,300 | — | — | 4,488,000 |
| Paul J. Taubman | CEO, Chairman | 2024 | 1,000,000 | 0 | 0 | — | — | 1,000,000 |
| Paul J. Taubman | CEO, Chairman | 2023 | 1,000,000 | 0 | 0 | — | — | 1,000,000 |
| David A. Travin | General Counsel | 2023 | 500,000 | 1,071,500 | 666,500 | — | — | 2,238,000 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 1,143 |
| 2023 | 1,012 |
| 2022 | 907 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 1,493,177,000 | 1,153,182,000 | 1,025,505,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | — | — | — |
| Operating Expenses | 1,222,608,000 | 975,573,000 | 824,034,000 |
| Operating Income | — | — | — |
| Net Income | 134,393,000 | 81,799,000 | 90,534,000 |
| Earnings Per Share Basic | 5.28 | 3.24 | 3.61 |
| Earnings Per Share Diluted | 4.92 | 3.12 | 3.51 |
| Weighted Average Shares Outstanding Basic | 25,454,445 | 25,255,327 | 25,077,835 |
| Weighted Average Shares Outstanding Diluted | 44,105,131 | 41,882,034 | 26,616,640 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 483,877,000 | 355,543,000 | 173,235,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 320,783,000 | 263,529,000 | 317,751,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | — | — | — |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 22,137,000 | 25,901,000 | 30,693,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | — | — | — |
| Total Assets | 1,635,334,000 | 1,434,978,000 | 1,050,652,000 |
| Accounts Payable | — | — | — |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | — | — | — |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | 733,691,000 | 573,814,000 | 291,094,000 |
| Common Stock | 340,000 | 324,000 | 310,000 |
| Retained Earnings | 228,594,000 | 118,332,000 | 60,969,000 |
| Accumulated Other Comprehensive Income | -1,661,000 | -467,000 | -2,274,000 |
| Total Shareholders Equity | 187,013,000 | 244,669,000 | 185,106,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 12,799,000 | 14,047,000 | 15,475,000 |
| Share Based Compensation Expense | 209,185,000 | 178,535,000 | 165,528,000 |
| Other Non Cash Income Expense | 1,888,000 | 935,000 | -2,793,000 |
| Change In Accounts Receivable | 55,920,000 | -51,904,000 | 32,497,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -11,031,000 | 33,515,000 | 42,659,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 530,950,000 | 441,534,000 | 242,731,000 |
| Purchases Of Marketable Securities | 369,988,000 | 328,767,000 | 143,929,000 |
| Sales Of Marketable Securities | 392,074,000 | 298,348,000 | 94,128,000 |
| Acquisition Of Property Plant And Equipment | 3,298,000 | 3,927,000 | 3,434,000 |
| Acquisition Of Business | 10,727,000 | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 8,061,000 | -34,346,000 | -53,235,000 |
| Tax Withholding For Share Based Compensation | 37,477,000 | 19,406,000 | 17,792,000 |
| Payments Of Dividends | 24,131,000 | 24,436,000 | 24,632,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 235,104,000 | 116,738,000 | 109,484,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 0 | 15,000,000 | 42,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -408,684,000 | -228,077,000 | -210,021,000 |
| Change In Cash | 128,334,000 | 182,308,000 | -27,246,000 |
| Cash At End Of Period | 483,877,000 | 355,543,000 | 173,235,000 |
| Income Taxes Paid | 36,082,000 | 23,288,000 | 28,578,000 |
| Interest Paid | 0 | 20,000 | 133,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 5.28 | 3.24 | 3.61 |
| Price To Earnings Ratio | 29.8883 | 31.4414 | 20.4127 |
| Earnings Growth Rate | 62.963 | -10.2493 | -15.0588 |
| Price Earnings To Growth Ratio | 0.4747 | -3.0677 | -1.3555 |
| Book Value Per Share | 35.4218 | 34.0983 | 30.288 |
| Price To Book Ratio | 4.4552 | 2.9875 | 2.433 |
| Ebitda | 183,274,000 | 119,134,000 | 134,587,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | 0.006 | 0.0095 | 0.0133 |
| Dividend Payout Ratio | 0.1796 | 0.2987 | 0.2721 |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 9,035,000 | 9,255,000 | 9,021,000 |
| Free Cash Flow | 521,915,000 | 432,279,000 | 233,710,000 |
| Return On Equity | 0.7186 | 0.3343 | 0.4891 |
| One Year Beta | 1.2671 | 0.6868 | 0.694 |
| Three Year Beta | 0.7891 | 0.7647 | 1.0186 |
| Five Year Beta | 1.0088 | 0.9991 | 1.0343 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Rafferty Emily K | Director | 2025-09-17 | 9 | A | 6,674 |
| Costos James | Director | 2025-09-17 | 14 | A | 10,386 |
| CURRIE PETER L S | Director | 2025-09-17 | 2 | A | 1,737 |
| RYAN THOMAS M | Director | 2025-09-17 | 17 | A | 12,831 |
| Travin David Adam | General Counsel | 2025-09-17 | 16 | A | 12,405 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Darwin Wealth Management, LLC | 2025-09-30 | 889 | 5 | 177.8 |
| TRUST CO OF TOLEDO NA /OH/ | 2025-09-30 | 533 | 3 | 177.6667 |
| CWM, LLC | 2025-09-30 | 32,000 | 181 | 176.7956 |
| HARBOR CAPITAL ADVISORS, INC. | 2025-09-30 | 1,570,000 | 8,833 | 177.7426 |
| NORDEN GROUP LLC | 2025-09-30 | 776,226 | 4,367 | 177.7481 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Grandeur Peak Global Trust | 2025-07-31 | Investor Class | GPROX | 2,800 | 500,136 | 0.3988 |
| Grandeur Peak Global Trust | 2025-07-31 | Institutional Class | GPRIX | 2,800 | 500,136 | 0.3988 |
| Grandeur Peak Global Trust | 2025-07-31 | Institutional Class | GUSYX | 16,942 | 3,026,180.04 | 2.1927 |
| Grandeur Peak Global Trust | 2025-07-31 | Institutional Class | GGSYX | 5,892 | 1,052,429.04 | 1.1716 |
| Grandeur Peak Global Trust | 2025-07-31 | Investor Class | GGSOX | 5,892 | 1,052,429.04 | 1.1716 |